Drug interactions between Emend and Xanax
Results for the following 2 drugs: |
|
|---|---|
| Emend (aprepitant) | |
| Xanax (alprazolam) | |
Interactions between your selected drugs
alprazolam ⇔ aprepitant
Applies to: Xanax (alprazolam) and Emend (aprepitant)
MONITOR: Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of benzodiazepines that are metabolized by CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant. According to the manufacturer, coadministration of aprepitant (125 mg single dose on day 1 and 80 mg/day on days 2 through 5) and midazolam (2 mg orally on days 1 and 5) resulted in an increase in the area under the plasma concentration-time curve (AUC) of midazolam by 2.3-fold on day 1 and 3.3-fold on day 5. The same regimen of aprepitant given for 3 days with intravenous midazolam (2 mg prior to initiation of aprepitant and on days 4, 8 and 15) increased midazolam AUC by 25% on day 4 but decreased it by 19% on day 8. Midazolam AUC on day 15 was similar to that observed at baseline. Thus, the effect of aprepitant on the pharmacokinetics of CYP450 3A4 substrates is expected to be greater when the substrates are administered orally as opposed to intravenously and may be altered following prolonged administration. Benzodiazepines known to be metabolized by CYP450 3A4 include alprazolam, diazepam, midazolam, and triazolam.
MANAGEMENT: Caution is advised if aprepitant or fosaprepitant is administered with benzodiazepines that are metabolized by CYP450 3A4. The potential for increased pharmacologic effects of the benzodiazepine, including central nervous system and respiratory depression, should be considered. The interaction is not expected to occur with lorazepam, oxazepam or temazepam, which are primarily metabolized via glucuronidation. Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.
See also...
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
